0000899243-23-012905.txt : 20230512
0000899243-23-012905.hdr.sgml : 20230512
20230512200922
ACCESSION NUMBER: 0000899243-23-012905
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230511
FILED AS OF DATE: 20230512
DATE AS OF CHANGE: 20230512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sullivan Lynne Marie
CENTRAL INDEX KEY: 0001727640
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38470
FILM NUMBER: 23917926
MAIL ADDRESS:
STREET 1: C/O SOLID BIOSCIENCES, LLC
STREET 2: 141 PORTLAND STREET, FIFTH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unity Biotechnology, Inc.
CENTRAL INDEX KEY: 0001463361
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264726035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 416-1192
MAIL ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cenexys, Inc.
DATE OF NAME CHANGE: 20130703
FORMER COMPANY:
FORMER CONFORMED NAME: Forge Inc
DATE OF NAME CHANGE: 20090504
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-11
0
0001463361
Unity Biotechnology, Inc.
UBX
0001727640
Sullivan Lynne Marie
C/O UNITY BIOTECHNOLOGY, INC.
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
0
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
40000
2.77
A
2033-05-11
Common Stock
40000
40000
D
Stock Option (Right to Buy)
99.60
2023-05-11
4
D
0
24000
0.00
D
2030-08-01
Common Stock
24000
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
24000
0.00
A
2030-08-01
Common Stock
24000
24000
D
Stock Option (Right to Buy)
41.80
2023-05-11
4
D
0
12333
0.00
D
2031-06-24
Common Stock
12333
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
12333
0.00
A
2031-06-24
Common Stock
12333
12333
D
Stock Option (Right to Buy)
10.60
2023-05-11
4
D
0
20000
0.00
D
2032-02-09
Common Stock
20000
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
20000
0.00
A
2032-02-09
Common Stock
20000
20000
D
The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
CFO and Head of Corporate Development
/s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
2023-05-12